segunda-feira, agosto 18, 2003

Azarito prezado leitor...
Data from a proof-of-concept trial came up short with Vivus Inc. (CA), which disclosed that its PDE5 inhibitor did not improved outcomes for men with premature ejaculation.

Nenhum comentário: